RecruitingNCT06379152
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Sponsor
Chongqing Medical University
Enrollment
400 participants
Start Date
Sep 20, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Adult aged ≥18 years old；
- Diagnosed with HFpEF.
- Diagnostic criteria including:
- left ventricular ejection fraction ≥ 50%;
- with the symptoms and/or signs of heart failure;
- Patients in sinus rhythm：BNP≥35pg/ml and/or NT-proBNP≥125pg/ml；Patients with atrial fibrillation：BNP≥105pg/ml and/or NT-proBNP≥365pg/ml.
Exclusion Criteria1
- LVEF less than 49% at any time
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06379152
Related Trials
Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
NCT042377011 location
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459564 locations
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
NCT070935281 location
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
NCT049457071 location
Transitions of Care Clinic (TOCC)
NCT069378271 location